Prosecution Insights
Last updated: May 29, 2026

Korea Research Institute Of Bioscience And Biotechnology

12 pending office actions • 11 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days

Portfolio Summary

12
Total Pending OAs
10
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
1
Due this week
2
Due this month
3
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 7 days (1)Due ≤ 30 days (2)Due ≤ 60 days (3)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
6
Medium (50%)
3
Easy (25%)
3
Unknown (25%)

Rejection Statute Mix

BucketCases
§103 only4 (33%)
§102 only1 (8%)
§112 only3 (25%)
Double-patenting + other1 (8%)
No statute on record3 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

12
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

120 h
Manual time on pending OAs
24 h
Time saved (low, 20%)
42 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
FETTEROLF, BRANDON J 1 49.5% +14.6%
VAJDA, KRISTIN ANN 1 84.1% +10.6%
KONOPKA, CATHERINE ANNE 1 58.8% +63.7%
REYNOLDS, FRED H 1 33.0% +39.2%
POPA, ILEANA 1 21.0% +14.9%
RODRIGUEZ, RAYNA B 1 32.4% +21.6%
BRANCH, CATHERINE S 1 85.4% +3.5%
LOUNTOS, GEORGE THEMISTOCLIS 1 0.0% +0.0%
TIWARI, VYOMA SHUBHAM 1 30.2% +46.7%
THUESON, HANNA MARIE 1 71.4% +30.8%

Quick Wins (2)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18561624 NOVEL CINNAMAMIDE DERIVATIVES AND USE THEREOF VAJDA, KRISTIN ANN 42d overdue
18015189 REAGENT COMPOSITION FOR DETECTING ILLICIT DRUGS AND SHEET KIT FOR DETECTING ILLICIT DRUGS COMPRISING SAME BRANCH, CATHERINE S 34d

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17767425 MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PRODUCTION METHOD THEREFOR, AND USE THEREOF LOUNTOS, GEORGE THEMISTOCLIS 45d overdue
18310969 COMPOSITION FOR PREVENTING OR TREATING PROGERIA AND NATURAL AGING THROUGH GENE EDITING POPA, ILEANA 33d

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18017339 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES RODRIGUEZ, RAYNA B 50d overdue
17686669 EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME THUESON, HANNA MARIE 46d overdue
18561624 NOVEL CINNAMAMIDE DERIVATIVES AND USE THEREOF VAJDA, KRISTIN ANN 42d overdue
18283589 COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL KONOPKA, CATHERINE ANNE 7d
18572480 PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR FOR TREATMENT OR TREATMENT OF RNA VIRAL INFECTIONS FETTEROLF, BRANDON J 16d
18310969 COMPOSITION FOR PREVENTING OR TREATING PROGERIA AND NATURAL AGING THROUGH GENE EDITING POPA, ILEANA 33d
17762313 PRODUCTION METHOD FOR INDUCED DOPAMINERGIC NEURONAL PROGENITORS, USING DIRECT REPROGRAMMING TIWARI, VYOMA SHUBHAM 34d
18312110 NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS REYNOLDS, FRED H 61d

Top Art Units

Art UnitApps
1631 2
1626 1
1622 1
1635 1
1658 1
1633 1
1628 1
1763 1
1652 1
1634 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18572480 PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR FOR TREATMENT OR TREATMENT OF RNA VIRAL INFECTIONS FETTEROLF, BRANDON J 1626 §103 Non-Final OA 16d Pending Dec 20, 2023
18561624 NOVEL CINNAMAMIDE DERIVATIVES AND USE THEREOF VAJDA, KRISTIN ANN 1622 §112 Non-Final OA 42d overdue Pending Nov 16, 2023
18283589 COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL KONOPKA, CATHERINE ANNE 1635 Other Non-Final OA 7d Pending Sep 22, 2023
18312110 NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS REYNOLDS, FRED H 1658 DPOther Non-Final OA 61d Pending May 04, 2023
18310969 COMPOSITION FOR PREVENTING OR TREATING PROGERIA AND NATURAL AGING THROUGH GENE EDITING POPA, ILEANA 1633 §103 Final Rejection 33d Pending May 02, 2023
18017339 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES RODRIGUEZ, RAYNA B 1628 §103 Non-Final OA 50d overdue Pending Jan 20, 2023
18015189 REAGENT COMPOSITION FOR DETECTING ILLICIT DRUGS AND SHEET KIT FOR DETECTING ILLICIT DRUGS COMPRISING SAME BRANCH, CATHERINE S 1763 §112 Non-Final OA 34d Pending Jan 09, 2023
17767425 MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PRODUCTION METHOD THEREFOR, AND USE THEREOF LOUNTOS, GEORGE THEMISTOCLIS 1652 Other Non-Final OA 45d overdue Pending Apr 07, 2022
17762313 PRODUCTION METHOD FOR INDUCED DOPAMINERGIC NEURONAL PROGENITORS, USING DIRECT REPROGRAMMING TIWARI, VYOMA SHUBHAM 1634 §103 Final Rejection 34d Pending Mar 21, 2022
17686669 EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME THUESON, HANNA MARIE 1638 §102 Non-Final OA 46d overdue Pending Mar 04, 2022
17598916 METHOD FOR PRODUCING CAR GENE-INTRODUCED NK CELLS AND USE THEREOF ZHU, JIANJIAN 1631 Other Non-Final OA 9d Pending Sep 28, 2021
17231278 HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME MIANO, JOSEPH PAUL 1631 §112 Non-Final OA 16d overdue Pending Apr 15, 2021

Managing Korea Research Institute Of Bioscience And Biotechnology's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month